In response to the increasing prevalence of obesity, the consumption of high-calorie and high-sugar foods and an unprecedented aging population, type 2 diabetes (T2D) continues to rise globally. The International Diabetes Federation reported that 589 million individuals aged 20 to 79 years had ...

Topline data from the TRIUMPH-2 and TRIUMPH-3 trials show substantial weight loss, improved glycemic control, and favorable changes in cardiometabolic risk markers with the investigational triple hormone receptor agonist in adults with obesity and type 2 diabetes or established cardiovascular disease.

A new Endocrine Society statement has reinforced the importance of accurate diagnosis and appropriate clinical assessment before testosterone replacement therapy (TRT) is initiated in men with hypogonadism.1 Published July 16, 2026, the statement reiterates that treatment should not be based on symptoms alone and highlights continuing uncertainties around the long-term safety of TRT. It follows an FDA expert panel that reviewed testosterone eligibility criteria in December 2025, Society comments submitted to the FDA in February 2026, and new prescribing-pattern data presented at ENDO 2026, the Society's annual meeting, in June.

Type 2 diabetes (T2D) is a progressive metabolic condition associated with obesity, cardiovascular disease and substantial morbidity and mortality.1 Despite the availability of multiple glucose-lowering therapies, a significant proportion of individuals with T2D fail to achieve recommended glycemic targets, ...

Achieving clinically meaningful weight loss and cardiometabolic targets is a key goal in the management of obesity and type 2 diabetes, particularly in people at elevated cardiovascular risk. In this analysis of the phase 3 STEP UP T2D trial, researchers evaluated the extent to which participants treated with semaglutide 7.2 mg, semaglutide 2.4 mg or placebo achieved predefined BMI, waist-to-height ratio and cardiometabolic targets after 72 weeks. In this interview, Prof. Carel le Roux discusses the rationale for assessing these treatment targets, the key findings from the analysis and their implications for the use of higher-dose semaglutide in people with obesity and type 2 diabetes.

Data presented at ENDO 2026 highlighted investigational approaches for difficult-to-control type 2 diabetes and acquired hypothalamic obesity, real-world outcomes with tirzepatide, and wider health impacts of GLP-1-based therapy.

Peripheral neuropathy is a common and clinically heterogeneous condition resulting from damage to the peripheral nervous system, affecting sensory, motor and autonomic fibers.1 Its diagnostic complexity stems from a broad spectrum of etiologies, including metabolic, autoimmune, infectious, toxic, neoplastic and ...

Dr Eric Ravussin discusses REDEFINE 1 findings from ECO 2026, highlighting improvements in physical function and preserved functional strength despite substantial weight loss with the GLP-1/amylin agonist combination CagriSema.

New interim data from OUTSTEP 1 reveal high levels of patient satisfaction with injectable semaglutide and underscore the importance of understanding patient experiences beyond clinical trials. “While still endorsing the ‘my responsibility only’ narrative, we are learning that a new attitude ...